Log In
Print
BCIQ
Print
Print this Print this
 

Vitekta, elvitegravir (GS 9137)

Also known as: JTK-303

  Manage Alerts
Collapse Summary General Information
Company Japan Tobacco Inc.
DescriptionHIV integrase inhibitor
Molecular Target HIV integrase
Mechanism of ActionHIV integrase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentApproved
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection; Treat HIV-1 infection in adults without known mutations associated with resistance to elvitegravir
Regulatory Designation

U.S. - Undisclosed Review (Treat HIV-1 infection);
EU - Standard Review (Treat HIV-1 infection);
Japan - Orphan Drug (Treat HIV-1 infection)

Partner

Gilead Sciences Inc.; Torii Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today